Octreotide Acetate (7 brand names, 3 dosage forms, 3 routes)
Available dosage forms: INJECTABLE, SOLUTION, CAPSULE, DELAYED RELEASE.
Routes of administration: INJECTION, SUBCUTANEOUS, ORAL.
Brand Names
- BYNFEZIA PEN
- MYCAPSSA
- OCTREOTIDE ACETATE
- OCTREOTIDE ACETATE (PRESERVATIVE FREE)
- OCTREOTIDE ACETATE PRESERVATIVE FREE
- SANDOSTATIN
- SANDOSTATIN LAR
Contraindications
Sensitivity to this drug or any of its components.
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: • Complete Atrioventricular Block [see Warnings and Precautions (5.1)] • Cholelithiasis and Complications of Cholelithiasis [see Warnings and Precautions (5.2)] • Hyperglycemia and Hypoglycemia [see Warnings and Precautions (5.3)] • Thyroid Function Abnormalities [see Warnings and Precautions (5.4)] • Steatorrhea and Malabsorption of Dietary Fats [see Warnings and Precautions (5.5)] • Changes in Vitamin B12 Levels [see Warnings and Precautions (5.6)]
Mechanism of Action
Octreotide acetate injection exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, VIP, secretin, motilin, and pancreatic polypeptide. By virtue of these pharmacological actions, octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and VIP secreting adenomas (watery diarrhea).
Overdosage
A limited number of accidental overdoses of octreotide acetate injection in adults have been reported. In adults, the doses ranged from 2,400 to 6,000 mcg/day administered by continuous infusion (100 to 250 mcg/hour) or subcutaneously (1,500 mcg 3 times a day). Adverse events in some patients included arrhythmia, complete atrioventricular block, hypotension, cardiac arrest, brain hypoxia, pancreatitis, hepatitis steatosis, hepatomegaly, lactic acidosis, flushing, diarrhea, lethargy, weakness, and weight loss. If overdose occurs, symptomatic management is indicated. Up-to-date information about the treatment of overdose can often be obtained from the National Poison Control Center at 1-800-222-1222.